Camurus AB (publ) (CAMRF) Research

Camurus AB (publ) is a pharmaceutical enterprise dedicated to the development and global commercialization of therapeutic solutions for severe and enduring medical conditions. Its operations span across Europe, Australia, the United States, Japan, and other international markets. Currently available products include Buvidal, a buprenorphine injection designed to manage opioid dependence; episil oral liquid, classified as a medical device for alleviating inflammatory and painful conditions within the oral cavity; and Brixadi, another treatment option for opioid use disorder. Beyond its established offerings, Camurus maintains a robust research and development pipeline featuring several promising drug candidates. CAM2038 is in development for the management of chronic pain. CAM2029 is progressing through Phase III clinical trials for acromegaly and neuroendocrine tumors, while also being evaluated in Phase II for polycystic liver diseases. Pulmonary arterial hypertension is the target for CAM2043 in Phase I trials, which is also undergoing Phase II investigation for Raynaud's phenomenon. Further in the pipeline, CAM2032 is in Phase II for prostate cancer, and CAM4072 has reached Phase III for genetic obesity disorders. CAM4071 is in Phase I for an endocrine disorder. Additionally, two compounds are in Phase I trials: CAM2047, aimed at chemotherapy-induced nausea and vomiting, and CAM2048, intended for postoperative pain relief. Established in 1991, Camurus AB (publ) maintains its corporate headquarters in Lund, Sweden.

Open Camurus AB (publ) (CAMRF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.